Branding/Logomark minus arrow-point-to-down Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 Icon/List no author result Created with Sketch.
Loading Scinapse...
Juan J. Gomez-Reino
University of Santiago de Compostela
371Publications
62H-index
18.8kCitations
Publications 371
Newest
Peter Nash38
Estimated H-index: 38
(University of Queensland),
Kamal Ohson3
Estimated H-index: 3
(Memorial University of Newfoundland)
+ 5 AuthorsJacob Aelion10
Estimated H-index: 10
Objective Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations beginning at week 2 in biological-naive patients with PsA. Methods Patients were randomised (1:1) to apremilast 30 mg twice daily or placebo. At week 16, patients whose swollen and tender joint counts had not improved by ≥10% were eligible for early escape. At week 24, all patients received apremilast through week 52. Results Among 219 randomised patients (apremilast: n=110; placebo: n=109), a signific...
7 Citations Download PDF Cite
Eva Salgado12
Estimated H-index: 12
,
José Ramón Maneiro Fernández + 1 AuthorsJuan J. Gomez-Reino62
Estimated H-index: 62
To perform a transcultural adaptation and validation of a Spanish version of the compliance questionnaire in rheumatology (sCQR). In this transversal study of transcultural adaptation of the sCQR, validity was evaluated in patients with rheumatoid arthritis (RA) and a minimum 6-month follow-up by determining compliance with the electronic prescription system in consuming steroids or nonbiologic disease-modifying antirheumatic drugs. A two-week retest was proposed to all patients. All patients co...
Source Cite
2018 in RMD Open
Peter C. Taylor38
Estimated H-index: 38
(University of Oxford),
Rieke Alten38
Estimated H-index: 38
+ 9 AuthorsDean Spurden3
Estimated H-index: 3
(Pfizer)
Background Despite the wide array of treatments available for rheumatoid arthritis (RA), some patients continue to report unmet clinical needs. We investigated the extent of inadequate disease control in patients with RA. Methods Data were drawn from the Adelphi 2014 RA Disease-Specific Program in France, Germany, Italy, Spain and the UK. Rheumatologists provided patient demographics, comorbidities, satisfaction with RA control and other clinical details. Patients reported their level of satisfa...
4 Citations Download PDF Cite
2018 in RheumatologyIF: 5.25
Dafna D. Gladman103
Estimated H-index: 103
(Toronto Western Hospital),
Arthur Kavanaugh72
Estimated H-index: 72
(University of California, San Diego)
+ 8 AuthorsC. Birbara19
Estimated H-index: 19
(University of Massachusetts Medical School)
Download PDF Cite
2018 in Scientific ReportsIF: 4.12
Rosario López-Rodríguez12
Estimated H-index: 12
,
Aida Ferreiro-Iglesias5
Estimated H-index: 5
+ 16 AuthorsIsidoro González-Álvaro29
Estimated H-index: 29
About 70 genetic studies have already addressed the need of biomarkers to predict the response of patients with rheumatoid arthritis (RA) to methotrexate (MTX) treatment. However, no genetic biomarker has yet been sufficiently validated. Here, we aimed to replicate a selection of 25 SNPs in the largest collection of patients up to date, which consisted of 915 patients treated with MTX. The change in disease activity (measured as ΔDAS28) from baseline was considered the primary outcome. In additi...
1 Citations Download PDF Cite
2018 in PLOS ONEIF: 2.77
Rosario López-Rodríguez12
Estimated H-index: 12
,
Eva Perez-Pampin17
Estimated H-index: 17
+ 23 AuthorsJavier Narváez31
Estimated H-index: 31
Supporting information:S1 Text. Information on selected previous studies and compatibility with the current study. It includes two tables. Table A: List of SNPs selected for this study with references and the corresponding quality control results in the current study. Table B: Characteristics of the patients included in previous studies compared with the current study. https://doi.org/10.1371/journal.pone.0196793.s001 (DOCX) S1 Dataset. Raw data with all the variables and patients considered in ...
Download PDF Cite
2018 in The LancetIF: 53.25
Atul Deodhar25
Estimated H-index: 25
(Oregon Health & Science University),
Alice B. Gottlieb81
Estimated H-index: 81
(New York Medical College)
+ 44 AuthorsJacob Aelion10
Estimated H-index: 10
Summary Background Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis. Methods We did a randomised, double-blind, placebo-controlled, phase 2a trial at 34 rheumatology and dermatology practices in Canad...
5 Citations Source Cite
Maria Victoria Hernández18
Estimated H-index: 18
,
S. Rodriguez + 14 AuthorsM.D. Ruiz
Background Persistence to treatment may be used as a surrogate marker for long-term treatment success Objectives To assess the probability of persistence on golimumab (GOL) up to 5 years after treatment initiation and the factors associated to longer persistence Methods BIOBADASER is the Spanish registry of biological drugs of the Spanish Society of Rheumatology and the Spanish Medicines Agency. A data-base analysis was done in October 2017 on all the patients who had initiated GOL for one of th...
Source Cite
Peter Nash38
Estimated H-index: 38
(University of Queensland),
Kamal Ohson3
Estimated H-index: 3
(Memorial University of Newfoundland)
+ 6 AuthorsJacob Aelion10
Estimated H-index: 10
Background ACTIVE is the first apremilast (APR) study to demonstrate onset of response to APR starting at Week 2 in biologic-naive subjects with psoriatic arthritis (PsA) who may have had exposure to 1 prior conventional disease-modifying anti-rheumatic drug. Objectives To determine the efficacy and safety of APR through Week 104 in the ACTIVE study. Methods Subjects were randomised (1:1) to receive APR 30 mg BID or placebo (PBO) for 24 weeks; thereafter, all subjects received active treatment w...
Source Cite
12345678910